After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …

The potential for future coronavirus outbreaks highlights the need to broadly target this
group of pathogens. We used an epitope-agnostic approach to identify six monoclonal …

The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion.
Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that …

Coronaviruses (CoVs) have caused outbreaks of deadly pneumonia in humans since the
beginning of the 21st century. The severe acute respiratory syndrome coronavirus (SARS …

Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus
that since its emergence in 2012 has caused outbreaks in human populations with case …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

B cell receptor (BCR) sequencing is a powerful tool for interrogating immune responses to
infection and vaccination, but it provides limited information about the antigen specificity of …

Conventional immunization strategies will likely be insufficient for the development of a
broadly neutralizing antibody (bnAb) vaccine for HIV or other difficult pathogens because of …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …